Fragmin In The Treatment Of Acute Deep-Vein Thrombosis With Or Without Pulmonary Embolism In Cancer Patients
To collect postmarketing data about Fragmin safety and efficacy in the treatment of deep vein thrombosis with or without pulmonary embolism in cancer patients.
Acute Deep Vein Thrombosis
DRUG: Fragmin (dalteparin sodium )
Number of Participants With Resolution of Deep Vein Thrombosis (DVT) of the Leg, Resolution criteria: clinical cure, defined as negative results of a compressive ultrasound examination of the leg, Month 6 or End of Treatment (EOT) (up to Month 6)
Number of Participants With Severe Bleeding That Resulted in a Transfusion of at Least 2 Units of Blood, Episodes of the severe bleeding (intracranial, intraspinal, intraocular, retroperitoneal, or in pericardial area) or bleeding from gastrointestinal (GIT), urinary system or gynecological bleeding resulted in a need for a transfusion of at least 2 units of blood. Subjects were assessed for severe bleeding as part of a systematic adverse event assessment., Baseline through Month 6 or EOT (up to Month 6)|Number of Participants With Severe Bleeding That Resulted in a Decrease in Hemoglobin Level of at Least 2.0 Grams Per Deciliter (g/dL), Episodes of the severe bleeding (intracranial, intraspinal, intraocular, retroperitoneal, or in pericardial area) or bleeding from GIT, urinary system or gynecological bleeding which led to a drop of hemoglobin of at least 2.0 g/dL. Subjects were assessed for severe bleeding as part of a systematic adverse event assessment., Baseline through Month 6 or EOT (up to Month 6)|Percent of Participants With and Without Pulmonary Embolism (PE), PE (diagnosed on the basis of ventilation-perfusion scan of the lungs or autopsy), Baseline, Week 2, Month 1, Month 3, and Month 6 or EOT (up to Month 6)|Number of Participants With Recurrent DVT, Defined as the number of participants with recurrence of DVT (diagnosed using compressive ultrasound examination or autopsy) after it has resolved (at the same location) or occurrence of new DVT at a new location on any of the post-baseline visits, Month 6 or EOT (up to Month 6)
Method: consecutive patient sampling. Patients were (are) included in the study in consecutive manner if they fulfilled the inclusion criteria and any of the exclusion criteria were not present.